FibroGen (STU:1FG) EPS (Basic) : €-1.13 (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is FibroGen EPS (Basic)?

FibroGen's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was €-0.15. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.13.

FibroGen's EPS (Diluted) for the three months ended in Sep. 2024 was €-0.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.13.

FibroGen's EPS without NRI for the three months ended in Sep. 2024 was €-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -1.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

FibroGen EPS (Basic) Historical Data

The historical data trend for FibroGen's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen EPS (Basic) Chart

FibroGen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.80

-1.73

-2.78

-2.96

-2.68

FibroGen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.61	-0.52	-0.30	-0.15	-0.15

FibroGen EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

FibroGen's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-260.641	-	0)	/	97.303
	=	-2.68

FibroGen's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-15.393	-	0)	/	100.515
	=	-0.15

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.13

FibroGen (STU:1FG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

FibroGen EPS (Basic) Related Terms

Thank you for viewing the detailed overview of FibroGen's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (STU:1FG) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

FGEN:USA FGEN:Mexico 0IL8:UK

Address

409 Illinois Street, San Francisco, CA, USA, 94158

Website

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

FibroGen Headlines

No Headlines